Semaglutide vs Phentermine: How These Weight Loss Medications Compare

If you have been researching weight loss medications, you have probably come across two names more than almost any others: phentermine and semaglutide. They are both used for weight management, and they are both prescribed by doctors. But they belong to entirely different classes of medications, they work through completely different mechanisms, and they come with very different expectations around how long you take them and what you can realistically achieve.

This article lays out what the research actually shows about each medication, where they differ, and how to think about which approach might fit your situation.

*Compounded semaglutide is not FDA-approved. The clinical trial data discussed below refers to FDA-approved branded semaglutide products. Compounded semaglutide has not been studied in the trials referenced here, and its outcomes cannot be assumed to match those of branded formulations. This article is for educational purposes only and does not constitute medical advice. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication.*

---

What Is Phentermine?

Phentermine has been around since 1959, making it one of the oldest weight loss medications on the market. It belongs to a class of drugs called sympathomimetic amines, which are chemically related to amphetamines. It works primarily in the brain by triggering the release of norepinephrine, a neurotransmitter that signals your body into a "fight or flight" state. That signal suppresses appetite and increases energy expenditure.

A few important things about phentermine that often get glossed over:

Short-term approval only. The FDA approved phentermine only for short-term use, generally interpreted as up to 12 weeks. Its approval predates modern clinical trial standards, and the long-term safety data that regulators now require from new medications simply does not exist for phentermine. Some practitioners prescribe it longer off-label, but the evidence base for extended use is limited.

It is a controlled substance. Phentermine is classified as a Schedule IV controlled substance under the Controlled Substances Act. That classification reflects its potential for dependence and its stimulant properties.

It is available in combination. Phentermine is also marketed in combination with topiramate (an anticonvulsant) under the brand name Qsymia. The combination product was approved by the FDA in 2012 for long-term use and has a more robust clinical evidence base than phentermine alone.

---

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist, a class of medications that mimic glucagon-like peptide-1, a hormone your gut releases in response to food. GLP-1 plays several roles in appetite and metabolism: it slows gastric emptying (food moves through your stomach more slowly), signals your brain to reduce appetite, and helps regulate blood sugar by stimulating insulin release.

Semaglutide was first approved for type 2 diabetes management (as Ozempic, weekly injection) and later for chronic weight management (as Wegovy, a higher-dose weekly injection). A daily oral tablet version (Rybelsus) is also approved for diabetes, and an oral version for weight loss was approved by the FDA in 2024.

Semaglutide is approved for long-term use as part of an overall weight management program that includes diet and exercise. It is not a short-term fix. The clinical trials that established its effectiveness ran for 68 weeks (about 16 months), and clinical guidance suggests many patients need to continue the medication to maintain results.

---

How They Work Differently

The contrast in mechanism matters a lot when you are thinking about what to expect.

Phentermine is primarily a stimulant. It suppresses appetite by activating your sympathetic nervous system. The effect is relatively immediate: most people notice appetite suppression within the first week. But the central nervous system adapts to stimulants over time, which is one reason phentermine's effects tend to diminish after several weeks and why long-term use raises concerns.

Semaglutide works through the gut-brain axis. It does not cause stimulant effects or cardiovascular stimulation. Instead, it affects multiple systems: slowing gastric emptying so you feel full longer, reducing appetite signals in the hypothalamus, and blunting the reward response to highly palatable foods. This last effect is what many patients describe as the quieting of "food noise" - the persistent background preoccupation with food that accompanies obesity for many people.

Because semaglutide's mechanism is slower-acting and works through hormonal pathways rather than direct stimulation, it takes longer to reach full effect. Most people start to see meaningful results at 8 to 12 weeks, with peak effects typically seen in the six-to-twelve month range.

---

Weight Loss Results: What the Clinical Data Shows

Phentermine

Phentermine monotherapy studies are mostly older, shorter, and methodologically weaker by current standards. Because approval predates modern requirements, there are no large, long-term randomized controlled trials for phentermine alone. A 2025 systematic review and meta-analysis in *Nature Medicine* that evaluated pharmacological obesity treatments found that phentermine produced modest short-term weight loss, but the evidence base was considerably thinner than for newer agents [1].

The phentermine-topiramate combination (Qsymia) has stronger evidence. The CONQUER trial, published in *The Lancet* in 2011, randomized 2,487 adults to phentermine/topiramate or placebo over 56 weeks. The high-dose combination achieved approximately 10.9% weight loss from baseline. The low-dose combination achieved about 7.8% [2]. These are combination results; phentermine alone consistently performs below these figures.

Semaglutide

The STEP 1 trial, published in the *New England Journal of Medicine* in 2021, studied semaglutide 2.4 mg weekly in 1,961 adults with obesity or overweight with at least one weight-related condition. After 68 weeks, participants in the semaglutide group lost an average of 14.9% of body weight, compared to 2.4% in the placebo group [3].

That 14.9% figure has become a benchmark in the field. It represents roughly three to four times the weight loss typically seen with phentermine monotherapy.

*Important disclaimer: The STEP 1 trial used Novo Nordisk's FDA-approved Wegovy (subcutaneous semaglutide 2.4 mg), not compounded semaglutide. Compounded semaglutide has not been evaluated in clinical trials of this scale. Whether compounded formulations produce equivalent outcomes is not established.*

---

How Long Each Medication Can Be Used

This is one of the most practically important differences.

Phentermine: FDA-approved for short-term use only. The traditional interpretation is 12 weeks or less. After that window, prescribing typically stops or changes. Weight lost during treatment often returns once phentermine is discontinued, particularly without major lifestyle modifications in place.

Semaglutide: Approved for long-term, chronic use as part of an ongoing weight management program. The STEP 4 trial (Rubino et al., JAMA, 2021) demonstrated what happens when semaglutide is discontinued: participants who switched to placebo after 20 weeks of treatment regained two-thirds of their lost weight within the following year [4]. This underscores that semaglutide works as an ongoing treatment, not a finite course - and stopping it typically reverses the benefit.

The contrast is notable. Phentermine is structurally designed as a short-term intervention. Semaglutide is structurally designed as a chronic disease management tool.

---

Side Effects: How They Differ

Phentermine Side Effects

Phentermine's stimulant mechanism produces predictable cardiovascular and neurological effects:

• Elevated heart rate and blood pressure (a meaningful concern in patients with hypertension)
• Insomnia, often significant enough to require attention
• Dry mouth, constipation
• Anxiety, restlessness, irritability
• Potential for tolerance and, with prolonged use, dependence

Because phentermine raises heart rate and blood pressure, it is contraindicated in patients with heart disease, uncontrolled hypertension, hyperthyroidism, or a history of substance abuse.

Semaglutide Side Effects

Semaglutide's most common side effects are gastrointestinal and relate directly to its mechanism of slowing gastric emptying:

• Nausea (most common, particularly in the dose-escalation phase)
• Vomiting
• Diarrhea or constipation
• Decreased appetite (intended effect, but can sometimes be excessive)

Serious but less common risks include pancreatitis, gallbladder disease (including gallstones), and, based on rodent studies, a theoretical concern about thyroid C-cell tumors. Semaglutide carries a boxed warning about thyroid cancer risk in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

Semaglutide does not increase heart rate or blood pressure in the same way phentermine does. The SELECT trial (Lincoff et al., NEJM, 2023) found that semaglutide 2.4 mg actually reduced major adverse cardiovascular events by 20% in adults with established cardiovascular disease and obesity, without diabetes [5].

---

Who Tends to Be a Better Candidate for Each

Phentermine may be considered when:

• A patient needs short-term appetite suppression as a bridge to longer-term lifestyle changes
• Cost is a major barrier and longer-term options are not accessible
• There are no cardiovascular contraindications
• The provider's clinical judgment supports short-term stimulant-based treatment

Semaglutide may be considered when:

• Long-term, sustained weight loss is the goal
• The patient has or is at risk for cardiovascular disease (semaglutide's CV evidence is strong)
• Blood pressure or heart rate concerns make stimulants inappropriate
• Previous short-term interventions have not produced durable results
• The "food noise" component of obesity is a significant driver for the patient

Many people who start with phentermine eventually look for something with longer-term data and more sustained results. That shift explains much of the search interest in how these medications compare.

---

The Bottom Line

Phentermine is a decades-old stimulant with limited long-term data, restricted to short-term use, and best understood as a short-bridge tool. It suppresses appetite effectively in the near term but offers few mechanisms for sustained weight maintenance.

Semaglutide is a newer class of medication with substantially larger weight loss effect sizes in clinical trials, a long-term approval pathway, and evidence of cardiovascular benefit. The trade-off is that it requires ongoing treatment to maintain results, the side effect profile (primarily GI) requires dose titration, and access and cost are real barriers for many patients.

Neither medication is a substitute for addressing the behavioral, nutritional, and lifestyle factors that support weight management over a lifetime. Both work best as part of a medically supervised program.

---

*This article is for educational purposes only and does not constitute medical advice. Compounded semaglutide is not FDA-approved and has not been studied in the clinical trials referenced here. The outcomes from branded semaglutide trials cannot be assumed to apply to compounded formulations. Individual results vary. Prescriva's compounded semaglutide is prepared by licensed 503A compounding pharmacies based on patient-specific prescriptions from licensed healthcare providers. Consult your provider before starting any weight loss medication.*

---

Ready to explore your options? [Check your eligibility](/eligibility)

---

Sources

1. McGowan B, et al. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. *Nat Med.* 2025. PMID: 41039116

1. Gadde KM, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER). *Lancet.* 2011. PMID: 21481449

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med.* 2021. PMID: 33567185

1. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity. *JAMA.* 2021. PMID: 33755728

1. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med.* 2023. PMID: 37952131